Download the Final Programme in pdf format.
Click on the presentation / session title to watch the video.

Select a timezone:
Athens, Greece (EEST) Brussels, Belgium (CEST) Sao Paolo, Brazil (GMT-3) Singapore / Beijing (GMT+8)


Novel nicotine-delivering products: toxicology, regulation, and health issues
Chairs: Demetrios Kouretas & Konstantinos Poulas
– Systems toxicology assessment of a representative e-liquid formulation using human primary bronchial epithelial cells, Diego Marescotti
– The flavoring and not the nicotine content of e-cigarette refill liquids affects the redox status of endothelial cells, Zoi Skaperda
– Smokeless tobacco induced biophysical and biochemical alterations in the plasma, erythrocytes, and platelets of panmasala users: subsequent biological effects, Narendra Maddu
– Reductions in biomarkers of exposure when switching from cigarette smoking to using a tobacco heating product for 6 months, Nathan Gale
– Toxicity assessment of a range of flavour eliquids, Damien Breheny


Opening remarks
Goals of the 3rd Scientific Summit on Tobacco Harm Reduction
Organizing Committee


Tobacco Control Policies – Do they work?
Chairs: Michael G. Toumbis & Karl E. Lund
Global tobacco control efforts — What has been done so far? Stamatoula Tsikrika
How are we addressing youth appeal and access? Lion Shahab
Smoking Cessation: Best practices to improve quit rates, Georgios S. Goumas
e-Cigarettes for smoking cessation, Paraskevi A. Katsaounou


Oral Presentations (submitted abstracts)
Anastasia Barbouni, Konstantinos Poulas, Demetrios Kouretas
Epidemiology & Social Issues

  • IQOS uptake and history of tobacco product use: findings from cross-sectional surveys in Japan, Italy, and Germany, Steve Roulet
  • Estimates of the population’s use of the JUUL Electronic Nicotine Delivery System may vary between survey questions that are accompanied and unaccompanied by an image of the JUUL device, Christopher Russell

Smoking cessation

  • Understanding the need to (re) innovate Tobacco Harm Reduction strategies for the Indian subcontinent, Nilesh Jain

Clinical Assessment and Harm Reduction

Tobacco Heating System 2.2 in mild to moderate chronic obstructive pulmonary disease subjects: An exploratory analysis, Francesco Sergio


Break || Posters Q & A (I)
Thematic categories:
1 – Epidemiology & Social Issues (perception risk, attractiveness, etc.)
2 – Toxicology and aerosol chemistry etc
3 – Biomarkers’ evaluation in animal or human studies
4 – Preclinical evaluation


Keynote lecture
Risk proportionate regulation and the science to support it: How rapidly can we end the epidemic of cigarette-caused disease? David T. Sweanor J.D.
Chair: Ignatios Ikonomidis


Public Health Policy and Regulation – What is expected in the future?

Chairs: Panos E. Vardas & David T. Sweanor J.D.
Longitudinal evaluation of Harm Reduction strategies worldwide, Karl Fagerström
What standards should authorities apply to alternative nicotine products to address challenges without losing potential benefits to adult smokers? Michael G. Toumbis
Public health risk communication: the FDA example, Clive Bates


Clinical Assessment and Research

Chairs: Peter Harper & Ignatios Ikonomidis
Update on e-cigarettes publications: Safety and effects on smokers, nonsmokers and youth, Konstantinos Farsalinos
Potential to reduce the risk of smoking-related diseases when switching from smoking to the tobacco heating system, Christelle Haziza
– Acute effects of heat-not-burn versus standard cigarette smoking in smokers, Charalambos Vlachopoulos
Novel smoking products and cardiovascular risk, Giuseppe Biondi Zoccai
Differential effects of heat-not-burn and conventional cigarettes on coronary flow, myocardial and vascular function, John Thymis


Hot topic
COVID-19 and nicotinic cholinergic system: an interaction which affects Public Health, Konstantinos Poulas & Konstantinos Farsalinos


Keynote lecture
Could the scientific and medical community play a role in making policy makers to reconsider the tobacco control strategies? David Khayat
Demetrios Kouretas


New Legislation on smoking control in Greece, Ioannis Faropoulos
Anastasia Barbouni


Panel Discussion
Should Tobacco Harm Reduction become a Public Health Policy tool globally?

Chair: Panos E. Vardas
Panelists: Ladislav Czemy, Stanimir Hasardzhiev, Karl Fagerstrom, Andrzej M. Fal, Fernando Fernandez Bueno, Charmaine Gauci, Karl E. Lund, Alex Wodak


Panel Discussion
The doctor’s dilemma:
Providing guidance on alternative smoking products to adult smokers amid controversy and change
Chair: Dimitri Richter
Panelists: Efrain Cambronero, Manuel Pais Clemente, Peter Harper, Piotr Kuna, Emil Toldy-Schedel, Michael G. Toumbis


Break || Posters Q & A (II)
Thematic categories:
5 – Regulatory issues
6 – Smoking cessation
7 – Clinical Assessment and Harm Reduction


Panel Discussion
Tobacco Harm Reduction in low- and middle-income countries

Chair: Nimesh G. Desai
Panelists: Amaliya Amaliya, Efrain Cambronero, Sharifa Ezat Wan Puteh, Kgosi Letlape, Fares Mili, Rajesh Sharan, Ron Christian G. Sison


Panel Discussion
Bioethics: Smokers right on credible information
Konstantinos Farsalinos
Panelists: Panagiotis D. Bamidis, Stanimir Hasardzhiev, Monica Gorgulho, Enrique Rios Espinosa


Smoking Control & Harm Reduction Association Announcement
– Mission, Values, Principles
– Position Statement & Voting


Closing Remarks
Organizing Committee